Industry News
Pharmaceutical Industry News
Bridge the gap between analytics…
Bridge the gap between analytics and patient care with data-driven strategies for better outcomes in patient support programs.
The companies and federal…
The companies and federal officials are engaged in talks and the deals could come together this week, according to reports from Endpoints News and The Wall Street Journal.
Even without accounting for the…
Even without accounting for the COVID-related declines that have punctuated Pfizer’s earnings in recent years, the company’s vaccines business appeared to be on the back foot in the third quarter, brought low by a U.S.
Eli Lilly is going for gold at the…
Eli Lilly is going for gold at the Milano Cortina 2026 Olympic and Paralympic Winter Games.
UCB has scored an FDA approval for…
UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian company, which has scored three nods in the U.S. for rare disease treatments in less than three
The Workers Left Out of Trump’s Drug-Manufacturing Renaissance
President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines.
Teva issued a voluntary recall of…
Teva issued a voluntary recall of 580,844 bottles of the widely used blood pressure medication prazosin hydrochloride, citing unacceptable levels of potentially cancer-causing impurities.
During Vertex’s third-quarter…
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several metrics that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending positively. One key figure, however, indicates otherwise as sales for
Arcutis Biotherapeutics has forged…
Arcutis Biotherapeutics has forged another celebrity partnership, signing up the actor Tori Spelling and her teenage daughter, Stella McDermott, to encourage people with inflammatory skin conditions to talk to their healthcare providers.
Insulet is taking diabetes…
Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger
A long-running confirmatory trial…
A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal. The development comes just as the company and the FDA work to formally limit the indication of
Patients hoping to get their hands…
Patients hoping to get their hands on a cheaper copycat of Johnson & Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection this summer that
Neurology-focused patient…
Neurology-focused patient groups’ perception of the pharma industry’s corporate reputation remains on a downward slope.
Kimberly-Clark has placed an…
Kimberly-Clark has placed an ambitious bet on a troubled counterpart, agreeing to buy out Johnson & Johnson’s consumer health spinout Kenvue for $48.7 billion.
After Roche’s Gazyva won an FDA…
After Roche's Gazyva won an FDA approval in lupus-related kidney disease, a phase 3 study now shows the med's worth in systemic lupus erythematosus, the most common type of lupus.
High-ranking FDA official George…
High-ranking FDA official George Tidmarsh, M.D., has tendered his resignation after an unconventional LinkedIn diatribe landed the senior drug regulator at the center of a lawsuit and an internal probe.
Eli Lilly is allotting $3 billion…
Eli Lilly is allotting $3 billion to establish an oral medicines manufacturing facility in Katwijk, the Netherlands, the company said on Monday.
F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company
The official, Dr. George Tidmarsh, has become embroiled in an ethical dispute and is now the target of a lawsuit over his actions involving certain drugs tied to a business associate.
Why Medicare Recipients Should Check Their 2026 Drug Plans Now
Fall enrollment is on. Some plans are raising premiums for Part D, which covers prescriptions, by $50 or more per month, while others are lowering them.
Caplyta, the crown jewel of…
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to unlock the lucrative major depressive disorder market as an adjunctive treatment to antidepressants.